Dwight Akerman

Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

CooperVision, Inc. engages in the manufacture of contact lenses. It offers monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. The firm’s products include MyDay; clariti 1day , Biofinity , Proclear and Avaira family. The company was founded in 1950 and is headquartered in Victor, NY.

Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia.

CPA Australia Ltd. is an Australian company that has been operating since 1954 and provides education, training, technical support, and advocacy services in the accounting profession. The private company is based in Southbank, Australia and has subsidiaries in Hong Kong. The company engages with governments, regulators, and industries to advocate for policies that stimulate sustainable economic growth. With over 166,000 members working in 100 countries and regions, CPA Australia is one of the world's largest accounting bodies. It was founded in 1886 by Andrew Lyell, Arthur Cleveland, Benjamin Doughty Smith, Thomas Brentnall, John McAlister Howden, Charles Morell Holmes, William Crellin, and Edward Langton. Andrew Paul Hunter has been the CEO of the company since 2018.

International Agency for the Prevention of Blindness provides promotional activities for the prevention of blindness. The company was founded in 1975 and is headquartered in London, the United Kingdom.

Boardworx Australia Pty Ltd. provides secretarial services. The company was founded by Leanne Ralph and is headquartered in Sydney, Australia.

Part of Fresenius SE & Co. KGaA, Fresenius Kabi Australia Pty Ltd. is a healthcare company based in Sydney, Australia that specializes in producing and marketing pharmaceuticals and medical devices for the therapy and care of critically and chronically ill patients worldwide. The Australian company's product portfolio includes lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company offers a range of products such as biosimilars, colloids, enteral nutrition, i.v. drugs, medical devices, and parenteral nutrition. The company is committed to finding the best solutions for patient needs and their philosophy of "caring for life" stands for their passion to care for people all around the world.

Governance Institute of Australia Ltd. provides education, support, and networking opportunities for directors, Australian company secretaries, governance advisers, and risk managers. The private company is based in Sydney, Australia. Megan Motto has been the CEO of the company since 2019.

The Trustee for Raise Foundation is a youth mentoring organization that focuses on youth safety, wellbeing, and mental health. The non-profit company is based in Sydney, Australia and was founded in 2008 by Vicki Condon, who has been the CEO since then. The Australian company offers mentoring programs in schools and other locations, with a mentoring model that is centered around youth safety. The organization measures its success through mentoring outcomes and achievements, and they also fundraise to support their programs.

SightGlass Vision, Inc. is an American clinical-stage life sciences company that focuses on ending nearsightedness in children. The private company is based in California and is developing innovative spectacle lenses based on groundbreaking research from the University of Washington. The company's unique diffusion optics technology is aimed at reducing the progression of myopia in children. SightGlass Vision was founded in 2016 by professors Jay and Maureen Neitz, Dr. James Kuchenbecker, and Dr. Thomas Chalberg, who is the CEO of the company.

Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France.

Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.